Evidence map›Paper›PMID 32323111›Full record

ReviewJournal of mammary gland biology and neoplasia2020

Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis.

M U J Oliphant, Deguang Kong, Hengbo Zhou, M T Lewis, H L Ford

Open access · greenAbstract readReview
In one paragraph

Review in Journal of mammary gland biology and neoplasia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Embryonic Mammary Gland Morphogenesis.Advances in experimental medicine and biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

M U J OliphantIntegrated Physiology Program, University of Colorado Anschutz Medical Campus, RC1-North, P18-6115, 12800 East 19th Ave, Aurora, CO, 80045, USA.
Deguang KongDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, RC1-North, P18-6115, 12800 East 19th Ave, Aurora, CO, 80045, USA.
Hengbo ZhouDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, RC1-North, P18-6115, 12800 East 19th Ave, Aurora, CO, 80045, USA.
M T LewisDepartments of Molecular and Cellular Biology and Radiology. Lester and Sue Smith Breast Center, Baylor College of Medicine. One Baylor Plaza BCM600, Room N1210, Houston, TX, 77030, USA.
H L FordIntegrated Physiology Program, University of Colorado Anschutz Medical Campus, RC1-North, P18-6115, 12800 East 19th Ave, Aurora, CO, 80045, USA. heide.ford@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USBaylor College of Medicine · USUniversity of Colorado Denver · US

Funding

Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate MetastasisR01CA224867 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., LEWIS, MICHAEL T. · 2019 to 2023
$3.2M
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progressionR01CA221282 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., ZHAO, RUI · 2017 to 2021
$3.2M
A mechanistic dissection of the role of Eya3 in breast cancer metastasisK00CA234940 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ZHOU, HENGBO · 2020 to 2023
$405k
Deciphering the role of Six2 in regulating cancer stem cell properties and promoting late-stage metastasis in breast cancer.K00CA223023 · NCI · HARVARD MEDICAL SCHOOL · PI OLIPHANT, MICHAEL UJ · 2019 to 2022
$365k
A mechanistic dissection of the role of Eya3 in breast cancer metastasisF99CA234940 · NCI · UNIVERSITY OF COLORADO DENVER · PI ZHOU, HENGBO · 2018 to 2019
$72k
Deciphering the role of Six2 in regulating cancer stem cell properties and promoting late-stage metastasis in breast cancer.F99CA223023 · NCI · UNIVERSITY OF COLORADO DENVER · PI OLIPHANT, MICHAEL UJ · 2017 to 2018
$68k
NCI NIH HHS F99 CA223023NCI NIH HHS F99 CA234940NCI NIH HHS K00 CA223023NCI NIH HHS K00 CA234940NCI NIH HHS R01 CA221282NCI NIH HHS R01 CA224867
6 · The paper itself

Abstract

Breast cancer initiation and progression are often observed as the result of dysregulation of normal developmental processes and pathways. Studies focused on normal mammary stem/progenitor cell activity have led to an understanding of how breast cancer cells acquire stemness-associated properties including tumor initiation, survival and multi-lineage differentiation into heterogeneous tumors that become difficult to target therapeutically. Importantly, more recent investigations have provided valuable insight into how key developmental regulators can impact multiple phases of metastasis, where they are repurposed to not only promote metastatic phenotypes such as migration, invasion and EMT at the primary site, but also to regulate the survival, initiation and maintenance of metastatic lesions at secondary organs. Herein, we discuss findings that have led to a better understanding of how embryonic and pluripotency factors contribute not only to normal mammary development, but also to metastatic progression. We further examine the therapeutic potential of targeting these developmental pathways, and discuss how a better understanding of compensatory mechanisms, crosstalk between pathways, and novel experimental models could provide critical insight into how we might exploit embryonic and pluripotency regulators to inhibit tumor progression and metastasis.

Indexed as

Epithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticBreastBreast NeoplasmsCell DifferentiationFemaleHumansNeoplasm MetastasisPluripotent Stem CellsSignal TransductionDevelopmental pathwaysMammary stem cellMetastasisMetastatic colonizatonMetastatic initiating cellPluripotencyTranscription factors

Identifiers

PMID32323111
PMCPMC7395869
OpenAlexW3018222990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.